BLISSGVS - Bliss GVS Pharma Limited Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

BLISSGVS

52/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹269.65-2.35(-0.86%)

Market Open as of May 8, 2026, 15:30 IST

Select time range

Pros

Past Returns: Outperforming stock! In past three years, the stock has provided 52.1% return compared to 9.8% by NIFTY 50.

Profitability: Recent profitability of 12% is a good sign.

Technicals: Bullish SharesGuru indicator.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Balance Sheet: Strong Balance Sheet.

Cons

Smart Money: Smart money looks to be reducing their stake in the stock.

Valuation
Market Cap	2.85 kCr
Price/Earnings (Trailing)	26.1
Price/Sales (Trailing)	2.99
EV/EBITDA	13.42
Price/Free Cashflow	53.91
MarketCap/EBT	16.97
Enterprise Value	2.85 kCr

Fundamentals
Revenue (TTM)	954.26 Cr
Rev. Growth (Yr)	4.9%
Earnings (TTM)	114.38 Cr
Earnings Growth (Yr)	-4%

Profitability
Operating Margin	18%
EBT Margin	18%
Return on Equity	9.79%
Return on Assets	8.17%
Free Cashflow Yield	1.85%

Growth & Returns
Price Change 1W	-2.6%
Price Change 1M	6.8%
Price Change 6M	110.8%
Price Change 1Y	140.6%
3Y Cumulative Return	52.1%
5Y Cumulative Return	19.4%
7Y Cumulative Return	7.6%
10Y Cumulative Return	9.6%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-75.44 Cr
Cash Flow from Operations (TTM)	105.91 Cr
Cash Flow from Financing (TTM)	-30.34 Cr
Cash & Equivalents	29.15 Cr
Free Cash Flow (TTM)	29.85 Cr
Free Cash Flow/Share (TTM)	2.83

Balance Sheet
Total Assets	1.4 kCr
Total Liabilities	231.88 Cr
Shareholder Equity	1.17 kCr
Current Assets	890.11 Cr
Current Liabilities	199.66 Cr
Net PPE	383.45 Cr
Inventory	119 Cr
Goodwill	7.71 Cr

Capital Structure & Leverage
Debt Ratio	0.03
Debt/Equity	0.03
Interest Coverage	13.39
Interest/Cashflow Ops	9.78

Dividend & Shareholder Returns
Dividend/Share (TTM)	1
Dividend Yield	0.37%
Shares Dilution (1Y)	0.40%
Shares Dilution (3Y)	1.6%

Technical Indicators
RSI (14d)	57.37
RSI (5d)	26.63
RSI (21d)	65.33
MACD Signal	Sell
Stochastic Oscillator Signal	Hold
SharesGuru Signal	Buy
RSI Signal	Hold
RSI5 Signal	Buy
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Shareholder Name	Holding %
NARSIMHA SHIBROOR KAMATH	30.66%
GULBARGA TRADING AND INVESTMENT PRIVATE	5.51%
ARJUN GAUTAM ASHRA	4.77%
GAUTAM RASIKLAL ASHRA	2.82%
ARIAN INVESTMENT LIMITED	2.45%
VIBHA GAGAN SHARMA	2.43%
SHRUTI VISHAL RAO	1.99%
COEUS GLOBAL OPPORTUNITIES FUND	1.76%
ARK GLOBAL EMERGING COMPANIES, LP	1.42%
QUADRATURE TRADING VCC - SUB-FUND NO. 1	1.23%
SHAILESH DALMIA	1.18%
GAGAN HARSH SHARMA	0.21%
RAMADAS VASUDEV KAMATH HUF	0.03%
PUNITA SHARMA	0.02%
SHIBROOR GOKULDAS KAMATH	0.01%
Geeta Narsimha Kamath	0%
Shibroor Ravidas Kamath	0%
Vishal Vijay Rao	0%
Shiv Kumar Sharma	0%
Radha Sharma	0%

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.43 LCr	58.94 kCr	+7.80%	+4.60%	40.61	7.52	-	-
CIPLA	Cipla	1.09 LCr	29.37 kCr	+10.80%	-9.40%	23.93	3.7	-	-
LUPIN	Lupin	1.09 LCr	28.38 kCr	+3.70%	+18.10%	20.38	3.83	-	-
DRREDDY	Dr. Reddy's Lab	1.08 LCr	36.09 kCr	+8.60%	+12.70%	19.35	2.99	-	-
AUROPHARMA	Aurobindo Pharma	86.38 kCr	33.73 kCr	+11.40%	+28.50%	24.77	2.56	-	-

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	5.2%	810	770	752	747	577	689
Other Income	25%	36	29	18	31	20	37
Total Income	5.9%	846	799	769	779	597	726
Cost of Materials	10.1%	373	339	330	385	260	257
Purchases of stock-in-trade	-4%	49	51	44	35	81	176
Employee Expense	16.8%	112	96	86	76	68	54
Finance costs	20.5%	8.12	6.91	10	4.74	5.51	5.41
Depreciation and Amortization	12%	29	26	19	17	17	13
Other expenses	10.6%	157	142	147	162	74	72
Total Expenses	10.4%	721	653	663	651	493	584
Profit Before exceptional items and Tax	-13.8%	126	146	106	128	104	142
Exceptional items before tax	96.7%	0	-29.2	0	-73.59	0	-13.38
Total profit before tax	7.8%	126	117	106	54	104	129
Current tax	18.8%	39	33	41	36	29	37
Deferred tax	-584.5%	-3.99	2.03	-11.51	-4.74	1.23	-3.09
Total tax	0%	35	35	29	31	30	34
Total profit (loss) for period	9.9%	90	82	77	23	74	95
Other comp. income net of taxes	-194.4%	-2.35	4.55	-6.38	-7.41	-0.51	3.67
Total Comprehensive Income	2.4%	88	86	70	16	73	99
Earnings Per Share, Basic	12.7%	8.02	7.23	6.83	1.46	6.64	9.43
Earnings Per Share, Diluted	13.7%	7.95	7.11	6.72	1.43	6.49	9.43
Debt equity ratio	6.4%	0.065	009	011	012	0	0
Debt service coverage ratio	-0.7%	0.0331	0.0396	0.0637	0.0173	0	0
Interest service coverage ratio	2.3%	0.2693	0.2522	0.1162	-	0	0

Description	(%) Q/Q	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024
Revenue From Operations	-10.7%	218	244	207	198	210	218
Other Income	-10.5%	18	20	35	12	15	5.04
Total Income	-10.6%	237	265	243	210	226	223
Cost of Materials	-9.6%	86	95	93	77	97	100
Purchases of stock-in-trade	1407.9%	20	2.26	21	14	19	12
Employee Expense	9.4%	36	33	31	28	30	28
Finance costs	-76%	1.49	3.04	5.47	1.68	1.08	3.83
Depreciation and Amortization	1.2%	8.35	8.26	8.2	8.04	7.55	6.98
Other expenses	-25%	46	61	43	49	37	34
Total Expenses	-13.9%	193	224	180	187	189	187
Profit Before exceptional items and Tax	5%	43	41	63	23	36	36
Exceptional items before tax	-	-2.51	0	0	0	0	0
Total profit before tax	0%	41	41	63	23	36	36
Current tax	7.7%	15	14	20	5.9	14	11
Deferred tax	117.1%	1.56	-2.27	-1.75	0.89	-3.14	-1.08
Total tax	36.4%	16	12	19	6.79	11	10
Total profit (loss) for period	-14.3%	25	29	44	17	26	26
Other comp. income net of taxes	142.8%	3.56	-4.98	5.85	-0.49	-0.09	-1.8
Total Comprehensive Income	17.4%	28	24	50	16	26	24
Earnings Per Share, Basic	-24.1%	2.2	2.58	4.08	1.47	2.27	2.31
Earnings Per Share, Diluted	-26%	2.14	2.54	4.04	1.46	2.27	2.29
Debt equity ratio	-	-	-	005	0.065	008	0
Debt service coverage ratio	-	-	-	0.0621	0.0211	0.0339	0.04
Interest service coverage ratio	-	-	-	0.1253	0.2023	0.3077	0.31

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	10.3%	667	605	598	636	466	442
Other Income	6.1%	36	34	51	33	18	35
Total Income	10%	703	639	649	669	483	477
Cost of Materials	10.8%	339	306	294	351	216	216
Purchases of stock-in-trade	-	0	0	0	2.01	46	18
Employee Expense	19.5%	99	83	73	65	59	44
Finance costs	16%	6.58	5.81	10	4.32	4.19	4.56
Depreciation and Amortization	13%	27	24	15	14	14	8.83
Other expenses	12.2%	130	116	121	118	62	61
Total Expenses	15.4%	609	528	533	545	392	355
Profit Before exceptional items and Tax	-15.5%	94	111	116	124	91	122
Exceptional items before tax	97.6%	0	-41.09	0	2.75	0	0
Total profit before tax	34.8%	94	70	116	126	91	122
Current tax	11.5%	30	27	34	33	23	32
Deferred tax	32.3%	-4.79	-7.55	-4.21	0.77	1.17	-2.53
Total tax	26.3%	25	20	30	34	24	29
Total profit (loss) for period	36%	69	51	85	93	68	92
Other comp. income net of taxes	-35.7%	-0.56	-0.15	-0.67	0.3	0.52	-0.26
Total Comprehensive Income	36.7%	68	50	85	93	68	92
Earnings Per Share, Basic	44.4%	6.56	4.85	8.234	8.97	6.54	8.95
Earnings Per Share, Diluted	45.9%	6.5	4.77	8.104	8.81	6.4	8.95
Debt equity ratio	0%	005	007	008	01	0	0
Debt service coverage ratio	-0.1%	0.028	0.0286	0.0679	0.044	0	0
Interest service coverage ratio	-10.7%	0.153	0.235	0.1293	-	0	0

Description	(%) Q/Q	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024
Revenue From Operations	-13.2%	165	190	163	156	180	183
Other Income	-64%	10	26	11	9.36	12	8.35
Total Income	-19.1%	175	216	174	165	191	191
Cost of Materials	-12.4%	79	90	89	69	88	91
Employee Expense	6.9%	32	30	28	25	26	24
Finance costs	-71.9%	1.48	2.71	5.11	1.3	0.67	3.45
Depreciation and Amortization	1.6%	7.8	7.69	7.68	7.43	6.96	6.39
Other expenses	-41.3%	28	47	31	39	31	32
Total Expenses	-19.8%	147	183	143	151	161	167
Profit Before exceptional items and Tax	-15.6%	28	33	31	14	30	24
Exceptional items before tax	-	-2.51	0	0	0	0	0
Total profit before tax	-25%	25	33	31	14	30	24
Current tax	-34.8%	7.52	11	13	3.95	10	8.74
Deferred tax	50.9%	-0.84	-2.75	-3.04	-1.04	-1.55	-1.9
Total tax	-25.8%	6.68	8.66	9.51	2.9	8.72	6.85
Total profit (loss) for period	-25%	19	25	21	11	21	17
Other comp. income net of taxes	-21.9%	-0.17	0.04	-0.1	-0.14	-0.12	-0.17
Total Comprehensive Income	-29.2%	18	25	21	11	21	17
Earnings Per Share, Basic	-43.7%	1.76	2.35	2	1.08	2	1.63
Earnings Per Share, Diluted	-45%	1.72	2.31	1.98	1.07	2	1.62
Debt equity ratio	-	-	-	004	005	006	0
Debt service coverage ratio	-	-	-	0.036	0.0201	0.03	0.02
Interest service coverage ratio	-	-	-	0.0697	0.1205	0.4554	0.3

Category	BLISSGVS	Pharmaceuticals
PE	26.10	36.29
PS	2.99	5.01
Growth	13.6 %	8.8 %

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	21.7%	29	24	33	23	42	25
Current investments	-	5.01	0	0	0.56	0.97	4.96
Loans, current	-1%	0.03	0.04	0.05	0.07	0.05	0.1
Total current financial assets	11.5%	737	661	661	632	549	497
Inventories	-5.6%	119	126	131	118	125	103
Current tax assets	-147.2%	0	3.12	2.92	2.91	1.35	1.62
Total current assets	8.7%	890	819	851	812	747	697
Property, plant and equipment	-3.5%	383	397	356	362	371	370
Capital work-in-progress	90%	39	21	24	7.83	1.82	2.8
Investment property	0%	0.68	0.68	0.68	0.68	0.69	0.69
Goodwill	0%	7.71	7.71	7.71	7.71	7.71	7.71
Non-current investments	16%	4.92	4.38	4.34	3.61	2.88	2.84
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	28.6%	46	36	20	12	55	59
Total non-current assets	7.6%	510	474	431	402	451	459
Total assets	7.6%	1,400	1,301	1,283	1,214	1,197	1,157
Borrowings, non-current	-36.8%	13	20	28	36	46	41
Total non-current financial liabilities	-9.4%	30	33	36	45	57	43
Provisions, non-current	-67.3%	2.1	4.36	3.37	2.54	1.9	2.69
Total non-current liabilities	-13.9%	32	37	42	51	62	46
Borrowings, current	-56%	23	51	55	52	40	57
Total current financial liabilities	7%	169	158	183	149	154	181
Provisions, current	661.1%	3.02	0.64	0.76	0	3.44	3.34
Current tax liabilities	585.9%	20	3.77	2.45	1.87	3.16	2.66
Total current liabilities	16.4%	200	172	193	160	172	193
Total liabilities	11.1%	232	209	234	211	234	239
Equity share capital	0%	11	11	11	10	10	10
Non controlling interest	-12.5%	36	41	38	36	33	34
Total equity	7%	1,168	1,092	1,048	1,003	963	917
Total equity and liabilities	7.6%	1,400	1,301	1,283	1,214	1,197	1,157

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	157.3%	16	6.83	15	14	26	19
Current investments	-	5.01	0	0	0	0	0
Loans, current	-19.4%	30	37	36	36	87	89
Total current financial assets	5.5%	692	656	651	625	613	585
Inventories	7.4%	88	82	98	89	98	74
Current tax assets	-171.9%	0	2.39	2.44	2.45	0.83	1.07
Total current assets	5.6%	811	768	805	773	764	730
Property, plant and equipment	-2.7%	358	368	325	330	334	325
Capital work-in-progress	90%	39	21	24	7.83	1.82	2.8
Investment property	0%	0.68	0.68	0.68	0.68	0.69	0.69
Non-current investments	0%	19	19	19	19	18	18
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	36.6%	57	42	33	25	61	66
Total non-current assets	9.5%	495	452	412	380	411	410
Total assets	7.1%	1,306	1,220	1,217	1,153	1,175	1,140
Borrowings, non-current	-36.8%	13	20	28	35	46	41
Total non-current financial liabilities	-9.7%	29	32	36	44	56	41
Provisions, non-current	-70.8%	1.98	4.36	3.33	2.47	1.82	2.61
Total non-current liabilities	-16.7%	31	37	39	47	63	49
Borrowings, current	-26.7%	23	31	34	31	16	36
Total current financial liabilities	30.5%	155	119	148	110	122	148
Provisions, current	496.1%	3.02	0.49	0.76	0	0	0
Current tax liabilities	-	7.36	0	0.48	0.54	2.69	1.74
Total current liabilities	37.1%	171	125	153	117	134	153
Total liabilities	25.6%	202	161	193	164	197	203
Equity share capital	0%	11	11	11	10	10	10
Total equity	4.3%	1,104	1,059	1,024	988	978	937
Total equity and liabilities	7.1%	1,306	1,220	1,217	1,153	1,175	1,140

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	20.5%	8.12	6.91	10	4.74	-	-
Change in inventories	-34.3%	-30.45	-22.42	15	-29.1	-	-
Depreciation	12%	29	26	19	17	-	-
Impairment loss / reversal	-103.6%	0	29	0	0	-	-
Unrealised forex losses/gains	73.2%	-5.33	-22.65	3	-3.88	-	-
Adjustments for interest income	27.3%	15	12	7.5	8.82	-	-
Share-based payments	11.3%	4.14	3.82	3.9	5.71	-	-
Net Cashflows from Operations	-23.7%	143	187	79	169	-	-
Interest paid	-	0	0	0	34	-	-
Income taxes paid (refund)	5.9%	37	35	45	0	-	-
Net Cashflows From Operating Activities	-30.5%	106	152	34	135	-	-
Cash payment for investment in partnership firm or association of persons or LLP	-	0	0	0	74	-	-
Proceeds from sales of PPE	702.5%	3.41	0.6	0.69	1.07	-	-
Purchase of property, plant and equipment	177.8%	76	28	94	0	-	-
Purchase of intangible assets	-	0.22	0	0	0	-	-
Interest received	274.1%	16	5.01	13	5.89	-	-
Other inflows (outflows) of cash	82%	-19	-110.1	78	-25.93	-	-
Net Cashflows From Investing Activities	42.9%	-75.44	-132.82	-7.75	-92.98	-	-
Proceeds from issuing shares	44.3%	2.89	2.31	2.04	2.28	-	-
Proceeds from exercise of stock options	-4.2%	0	0.04	0	0	-	-
Proceeds from borrowings	285.7%	55	15	40	11	-	-
Repayments of borrowings	208.7%	72	24	54	26	-	-
Payments of lease liabilities	88.6%	4.49	2.85	1.37	2.12	-	-
Dividends paid	1.4%	5.45	5.39	5.44	5.33	-	-
Interest paid	14.1%	6.82	6.1	6.3	2.96	-	-
Net Cashflows from Financing Activities	-43.2%	-30.34	-20.89	-24.94	-23.73	-	-
Effect of exchange rate on cash eq.	21.7%	0.1	-0.15	1.4	0	-	-
Net change in cash and cash eq.	68.2%	0.23	-1.42	3.02	19	-	-

BLISSGVS - Bliss GVS Pharma Limited Share Price

BLISSGVS

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

BLISSGVS

BLISSGVS - Bliss GVS Pharma Limited Share Price

BLISSGVS

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

BLISSGVS

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Bliss GVS Pharma Limited do?

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Bliss GVS Pharma Limited do?

Important Disclosure & Data Context